<DOC>
	<DOCNO>NCT01682759</DOCNO>
	<brief_summary>This trial ass safety efficacy omarigliptin ( MK-3102 ) compare sulfonylurea , glimepiride , Type 2 diabetes mellitus participant inadequate glycemic control metformin monotherapy . The primay hypothesis study 54 week , mean change baseline hemoglobin A1C ( A1C ) participant treat omarigliptin non-inferior compare participant treat glimepiride .</brief_summary>
	<brief_title>A Study Safety Efficacy Omarigliptin ( MK-3102 ) Compared With Glimepiride Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Metformin ( MK-3102-016 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosed Type 2 diabetes mellitus On stable dose metformin ( ≥1500 mg/day ) least 12 week inadequate glycemic control Females reproductive potential agree remain abstinent use partner use acceptable method birth control History type 1 diabetes mellitus history ketoacidosis Treated antihyperglycemic agent ( AHA ) therapy protocolrequired metformin within prior 12 week study participation omarigliptin time prior signing inform consent On weight loss program maintenance phase start weight loss medication past 6 month undergone bariatric surgery within 12 month prior study participation Medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus New worsen coronary heart disease , congestive heart failure , myocardial infarction , unstable angina , coronary artery intervention , stroke transient ischemic neurological disorder within past 3 month History malignancy ≤5 year prior study participation except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Pregnant breastfeeding , expect conceive donate egg trial , include 21 day follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>diabetes</keyword>
</DOC>